UnitedHealthcare
Sandostatin 200 Mcg/Ml Soln (octreotide acetate)
Hormones : Drugs for Growth
  • Prior Authorization: Documented Diagnosis: Yes
    Duration: 12 Month(s)

  • Neuroendocrine Tumor (NET):
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: No
    Duration of Reauthorization: = 12 month(s)

    Oncology: Carcinoid Syndrome:
    Duration: 12 Month(s)
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: No
    Duration of Reauthorization: N/A
    Requires diagnosis of Carcinoid syndrome with diarrhea: No
    Concomitant Therapy Required with Somatostatin Analog Therapy: No
    Patient Required to Try Increased Dosage of Sandostatin: No